Obed Akwasi Aning, Chit Fang Cheok, Drugging in the absence of p53, Journal of Molecular Cell Biology, Volume 11, Issue 3, March 2019, Pages 255–264, https://doi.org/10.1093/jmcb/mjz012
Abstract:
Inactivation of the p53 gene is a key driver of tumorigenesis in various cancer cohorts and types. The quest for a successful p53-based therapy that holds the promise of treating more than half of the cancer population has culminated in extensive knowledge about the role and function of p53 and led to new proposed innovative strategies against p53-defective cancers. We will discuss some of these latest studies with a focus on metabolic regulation and DNA damage response and also highlight novel functions of p53 in these pathways that may provide a contemporary rationale for targeting p53 loss in tumors.
License type:
http://creativecommons.org/licenses/by-nc/4.0/
Funding Info:
This work was supported by the Institute of Molecular and Cell Biology (IMCB), Agency of Science, Technology and Research (A*STAR), Singapore
Description:
This is a Version of Record published in the Journal of Molecular Cell Biology following peer review. The version of record Obed Akwasi Aning, Chit Fang Cheok, Drugging in the absence of p53, Journal of Molecular Cell Biology, Volume 11, Issue 3, March 2019, Pages 255–264, https://doi.org/10.1093/jmcb/mjz012 is also available online at: https://doi.org/10.1093/jmcb/mjz012